vedolizumab + nivolumab + ipilimumab

This is a **combination regimen** consisting of vedolizumab, nivolumab, and ipilimumab, evaluated in clinical trials for patients with advanced melanoma. - **Vedolizumab** is a monoclonal antibody that targets the integrin alpha4beta7, inhibiting lymphocyte trafficking to the gut and acting as an immunomodulator. It is approved for the treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease). - **Nivolumab** is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor that enhances antitumor immune responses. - **Ipilimumab** is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also a checkpoint inhibitor, which promotes T cell activation and proliferation. This triple-drug combination was studied to determine whether vedolizumab could reduce or prevent gastrointestinal immune-related adverse events (AEs) associated with the approved standard-of-care combination of nivolumab plus ipilimumab. The trial in advanced melanoma was terminated early due to toxicity concerns and did not demonstrate a reduction of GI toxicity compared to standard therapy[1].